Now shows investor logos: CSEM, Kickfund, Innosuisse Innovation Project, University of Fribourg, Venture Kick, Innosuisse Innovation Cheque, PHRT, Innosuisse Initial Coaching and 1 more.
Observed on the company’s website; business claims are not independently verified.
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself
3D-bioprinted lab grown alternatives to animal experiments
Compagos enables personalized treatment with human organoids for the treatment of osteoporosis and rare bone disease.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
September 2023 – November 2026 · 8 captures · latest observed messagingBuilding the future of biohardware for bone health
CompagOs advances functional bone biology through biohardware, enabling translational research for earlier insight into skeletal complications in cancer.